Interface-Engineered Nanocarriers for Translational and Patient-Centric Topical Therapy in Psoriasis [0.03%]
用于银屑病转化和以患者为中心的局部治疗的界面工程纳米载体
Vivek Singh,Urushi Rehman,Taha Alqahtani et al.
Vivek Singh et al.
Psoriasis is a chronic, immune-mediated dermatological disorder characterized by keratinocyte hyperproliferation and persistent inflammation, representing a significant therapeutic challenge. Conventional topical therapies are often limited...
Pharmacological Evaluation of Novel N- and C-Modified Peptide Analogues of VV-hemorphin-5 and VV-hemorphin-7 as Potential Agents With Anti-Seizure Activity [0.03%]
新型N-和C-修饰的肽类似物VV-血morphin-5和VV-血morphin-7的药理学评价作为潜在的抗惊厥药物
Jana Tchekalarova,Miroslav Rangelov,Nadezhda Todorova et al.
Jana Tchekalarova et al.
Recently, a series of N- and C-modified hemorphins have been synthesized, characterized and evaluated for their antibacterial potency. These analogues included amino acids such as cysteine (Cys), glutamic acid (Glu), and histidine (His), as...
Targeted Delivery of Thymoquinone-Encapsulated Polyethyleneimine/Poly (Lactic Acid) Nanoparticles Into Breast Cancer Cells [0.03%]
聚乙烯亚胺/聚(L乳酸)载檀香茋纳米粒靶向递送至乳腺癌细胞中
Jeganpandi Senthamarai Pandi,Parasuraman Pavadai,Ewa Babkiewicz et al.
Jeganpandi Senthamarai Pandi et al.
Breast cancer is the most commonly diagnosed cancer globally, predominantly affecting older women. Thymoquinone (TQ) is a natural therapeutic agent that exerts anticancer efficacy. However, its pharmacological effects are restricted by inad...
Next-Generation Therapies for Bone Cancer: Targeted Therapy, Immunotherapy, and Nanomedicine Innovations [0.03%]
骨癌下一代疗法：靶向治疗、免疫治疗和纳米医学创新
Kun Wang,Epiphane K Silli,Huixia Lv et al.
Kun Wang et al.
Bone cancer remains a challenging malignancy, with high mortality rates in advanced or metastatic stages. Recent therapeutic advances have increasingly focused on integrating targeted therapy, immunotherapy, and chemotherapy with nanodrug d...
Rational Design of Triazole Hydrazide Derivatives With Imidazo[2,1-b]thiazole Scaffolds as Targeted EGFR Inhibitors in NSCLC [0.03%]
合理设计三唑肼衍生物及其并咪唑并噻唑支架作为靶向EGFR在NSCLC抑制剂
Mohamed K Elgohary,Mahmoud S Elkotamy,Zainab M Elsayed et al.
Mohamed K Elgohary et al.
A novel series of triazole hydrazide derivatives 8a-o was rationally designed, synthesized, and systematically evaluated for their anticancer potential. Cytotoxicity screening against A549 lung adenocarcinoma cells identified compounds 8a-d...
Esketamine Protects the Blood-Brain Barrier Against Sepsis-Associated Brain Injury by Regulating the BDNF/TrkB Pathway [0.03%]
艾斯氯胺酮通过调节BDNF/TrkB信号通路保护血脑屏障抵抗脓毒症相关脑损伤
Weiqin Wei,Guofeng Wu,Yi Ge et al.
Weiqin Wei et al.
This study was designed to explore the effects of esketamine on cognitive deficits and blood-brain barrier (BBB) dysfunction in sepsis-associated encephalopathy (SAE). An in vivo SAE model was generated through the administration of lipopol...
Potent Therapeutic Efficacy of 9-Bromo-Noscapine Against Breast Cancer Cells Via Enhanced Bioavailability of the Noscapine-Cyclodextrin Inclusion Complex [0.03%]
通过增强诺斯卡品-环糊精包合物的生物利用度提高9-溴诺斯卡品对乳腺癌细胞的显著治疗效果
Namita Bhoi,Lilesh Kumar Pradhan,Dibya Ranjan Sahoo et al.
Namita Bhoi et al.
The poor bioavailability and low therapeutic indices of conventional cancer therapeutics hinder their efficacy despite their promising anticancer potential. This study presents an improved solubility and enhanced drug delivery system agains...
Recent Progress of Molecular Design and Activities of Spleen Tyrosine Kinase (SYK) Inhibitors [0.03%]
spleyn酪氨酸激酶(syk)抑制剂的分子设计及活性研究最新进展
Jiayi Shen,Jieman Lin,Anzhi Li et al.
Jiayi Shen et al.
Spleen tyrosine kinase (SYK), a non-receptor tyrosine kinase, serves as a pivotal regulator in multiple intracellular signaling pathways, particularly those involved in immune responses. Dysregulated SYK activation has been strongly implica...
NanoMIPs: Molecularly Imprinted Cavities for Smart and Controlled Anti-Cancer Drug Release [0.03%]
纳米分子印迹聚合物：智能控释抗癌药物的分子印迹空腔技术
Rabab Fatima
Rabab Fatima
The inception of molecularly imprinted polymer technology at the nanoscale has marked a major advancement in targeted cancer therapy and diagnostics, representing the first systematic distribution of synthetic substitute to monoclonal antib...
Next-Generation Proteolysis-Targeting Chimeras in Precision Oncology: Multifunctional Designs, Emerging Modalities, and Translational Prospects in Targeted Protein Degradation [0.03%]
精准肿瘤学中下一代蛋白酶靶向嵌合体的设计、模式及转化前景：功能设计、新兴模式以及靶向蛋白降解的临床应用
Mohamed S Nafie,Mohamed K Diab,Asmaa S A Yassen et al.
Mohamed S Nafie et al.
Proteolysis-targeting chimeras (PROTACs)-mediated protein degradation has been recently developed as a game-changing approach in oncology drug development. It represents a paradigm shift from traditional enzyme inhibition to selective prote...